https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval
0
0
FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval - FDA.gov
7/6/23 at 8:35pm
Organization
FDA.gov
Author
Office of the Commissioner
30 words
0
Comments
The FDA converted Leqembi (lecanemab-irmb), indicated to treat adult patients with Alzheimer’s Disease, to traditional approval.
You are the first to view
Create an account or login to join the discussion